COVID - 19 vaccine still shows strong protection, says Moderna

2 minutes
COVID - 19 vaccine still shows strong protection, says Moderna

NEW YORK, April 13- Moderna Inc. said on Tuesday that its COVID 19 vaccine showed strong protection against the illness six months after people got their second shot, with efficacy of more than 90 percent against all cases of COVID 19 and more than 95 percent against severe COVID 19.

The vaccine maker, which will update investors on the progress of its vaccines at an event on Wednesday, said the six-month follow-up of its original late-stage study of the vaccine showed that the vaccine efficacy remained consistent with its previous updates.

The company has also started testing new versions of the vaccine that target a concerning new variant of the coronavirus, which was first identified in South Africa and known as B.


It spelled both versions of the vaccine that it is testing, including a multivalent vaccine which combines the previous one with the new antibody titers in mice, with the multivalent setting the broadest level of immunity.

The company in March began testing three approaches to boosting the vaccine in order to protect against new variants. Moderna's vaccine is approved or authorized for use in more than 40 countries.

It uses messenger RNA technology, which contains instructions for human cells to make proteins that mimic part of the coronavirus. The instructions spur the immune system into action, turning the body into a virus-zipping vaccine factory.

The vaccines contain no real virus; the Cambridge, Massachusetts-based company said that by Monday it has delivered around 132 million doses globally, including 117 million doses for the United States. The company said it is on track to supply the nation with 300 million doses of vaccine by the end of July.

Moderna said its supply chain outside the United States was up around a quarter behind the U.S. supply chain and continues to ramp up.

The company said its average US selling price in the first quarter was around$ 15.40 per dose, excluding a roughly$ 1 billion payment from the Biomedical Advanced Research and Development Authority which is part of the U.S. Department of Health and Human Services.

Outside the United States, the prices ranged from$ 22 to$ 37 per dose, it said. Then there's the old-fashioned, English slogan: `` Solders know about Us '', and that ’ s why we love ourselves.

  • Comments
Loading comments...